Alkermes (ALKS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

ALKS · Stock Price

USD 35.40+5.27 (+17.49%)

Market Cap: $5.9B

Historical price data

Market Cap: $5.9BPipeline: 92 drugs (35 Phase 3)Patents: 20Founded: 1987HQ: Dublin, Ireland

Overview

Alkermes is a global biopharmaceutical leader focused on developing medicines for complex psychiatric and neurological disorders, leveraging deep neuroscience expertise. Its strategy integrates discovery, development, manufacturing, and commercialization, with a current pipeline anchored by late-stage candidates in sleep disorders and serious mental illness. Recent achievements include the initiation of Phase 3 studies for alixorexton in narcolepsy and the completion of the Avadel Pharmaceuticals acquisition, solidifying its position in sleep medicine.

PsychiatryNeurologySleep DisordersAddiction

Technology Platform

Integrated neuroscience expertise focused on patient-inspired science, novel small molecule discovery, and advanced formulation/delivery technologies for CNS disorders.

Pipeline

92

92 drugs in pipeline35 in Phase 3

Drug	Indication	Stage
Naltrexone for extended-release injectable suspension + Oral...	Opioid-Related Disorders	Approved
XR-NTX 380 mg, intramuscular injection + Placebo intramuscul...	Alcohol Use Disorder	Approved
Aripiprazole Lauroxil	Schizophrenia	Approved
VIVITROL 380 mg + Placebo	Alcohol Dependence	Approved
Aripiprazole Lauroxil	Schizophrenia	Approved

Funding History

3

Total raised:$798M

Debt$450MUndisclosedNov 15, 2017

Debt$300MUndisclosedMar 15, 2015

IPO$48MUndisclosedJun 27, 1991

FDA Approved Drugs

4

LYBALVINDAMay 28, 2021

ARISTADA INITIO KITNDAJun 29, 2018

ARISTADANDAOct 5, 2015

Opportunities

The Phase 3 oral orexin agonist alixorexton represents a potential blockbuster opportunity in narcolepsy and could establish Alkermes as a leader in sleep medicine.

The recent Avadel acquisition provides an immediate revenue stream and broadens the sleep disorder portfolio, while label expansion into pediatric serious mental illness offers lifecycle management for a key commercial asset.

Risk Factors

The company's valuation is heavily dependent on the success of the high-profile Phase 3 alixorexton program, with clinical failure posing a major downside risk.

Additional risks include intense competition in both sleep and psychiatry markets, regulatory hurdles, and the challenge of integrating the Avadel acquisition.

Competitive Landscape

In narcolepsy, Alkermes faces competition from Jazz Pharmaceuticals' Xywav/Xyrem and Takeda's Wakix, with other orexin agonists in development. In schizophrenia, Lybalvi competes in a crowded branded segment against agents like Vraylar and Rexulti, as well as generics. Success hinges on differentiated efficacy and safety profiles.